TIGIT and melanoma: Moreover, TIGIT competes for its ligands CD112 and CD155 with the co‐stimulatory receptor CD226 which, unlike conventional T cells, is associated with functionally suppressed Treg cells.132 This study suggests that the CD226/TIGIT ratio correlates with Treg cell stability, and clinical outcome in individuals with melanoma.